Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05417555

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease.

The main questions the study seeks to answer are:

1. Can LIFUP increase brain activity in the targeted area? 2. Can LIFUP improve memory in people with MCI and mild AD? 3. Can LIFUP improve connectivity of memory networks in the brain?

Participants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCLA Semel Institute for Neuroscience and Behavior

Los Angeles, California, 90024, United States

Location status: Recruiting

Location contact

Natalie Rotstein

CONTACT

[email protected]

3107940077

Sabrina Halavi

CONTACT

[email protected]

3107940077

Susan Y Bookheimer, PhD

PRINCIPAL_INVESTIGATOR

About this study

This is a proof of concept trial of Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex in patients with amnestic MCI and Mild Alzheimer's Disease. Participation in the study will entail one Zoom intake session, three in-person sessions and three remote Zoom follow-up sessions over the course of about five weeks. The in-person sessions will take about 5 hours for the first and 3 hours for the following two. The Zoom intake session will take 1-2 hours, and the Zoom follow-up sessions will take about 2 hours each. Participants will be asked to complete questionnaires and tests of learning and memory, have their blood drawn, undergo painless ultrasound stimulation to a part of their brain related to memory, and complete MRI scans of their brain. LIFUP will be administered inside of the MRI scanner, so that we can measure changes in brain activity in real-time.

At the start of the study, you will be randomly assigned to one of four different groups that determines the amount of LIFUP stimulation you will receive. You have an equal chance of being assigned to each group. Participants in one of the three active stimulation groups will receive either 1 dose, 2 doses, or 3 doses of LIFUP at their second in-person session, and will receive the same dose again at their third in-person session. Participants in the placebo group will receive no LIFUP stimulation at either MRI/LIFUP session (in-person visits 2 and 3). However, if at the end of our study, the treatment has been shown to be effective, and you were a placebo subject, we will offer you a free session using the most effective dose.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Amnestic MCI or Mild Alzheimer's diagnosis
  • Age 50-90
  • English-speaking
  • Ability to provide informed consent
  • Normal or corrected-to-normal hearing and vision

Exclusion criteria

GENERAL

  • Participation in another clinical trial
  • Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)
  • Moderate to Severe Alzheimer's
  • Inability to provide informed consent

MRI-Related:

  • Weight exceeding 275 pounds
  • Pregnancy, suspicion of pregnancy, or attempting to become pregnant
  • Claustrophobia
  • Difficulties during previous MRIs
  • Top permanent retainer (bottom only is okay), 5 or more non-removable gold-teeth, metal braces, top spacers, and/or palate expanders
  • Any of the following implants: Cardiac Pacemaker, Aneurysm clips, Cochlear implants, Defibrillator, Electrodes or wires, Magnetically-activated device, Spinal cord stimulator, Infusion or insulin pumps, Implanted drug infusion device, Deep brain stimulation device
  • Non-removable hairpieces, hairpiece extensions, and/or piercings
  • Facial tattoos or permanent makeup
  • Metal implants that are MR-incompatible, or where participant is unable to provide sufficient information to determine MR compatibility
  • Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object entered the body and participant lacks doctor's confirmation that it was fully removed

Medical:

  • Diagnosis of one or more of the following neurological disorders: Parkinson's disease, Lou Gehrig's disease (ALS), Multiple sclerosis, Cerebral Palsy
  • Diagnosis of one or more of the following genetic disorders: Cystic Fibrosis, Sickle Cell Disease
  • Diagnosis of one or more of the following psychiatric disorders: Bipolar, Psychosis
  • Psychiatric illness that has not been controlled for at least two months (if controlled >2 months, with or without medication, they are not exclusionary)
  • Severe lung, liver, heart, and/or kidney disease/s (e.g., heart failure, liver failure, and etc...)
  • Diagnosis of thyroid disorder or change of thyroid medication dose within the last 3 months
  • Cancer treatment/s with chemotherapy and/or radiation to head and neck, or stage 4 (metastatic) cancer
  • Autoimmune disorder or viral infection such as HIV, COVID 19, or hepatitis C that has caused current problems with cognition/memory
  • History of substance abuse in the past year
  • History of stroke (Transient ischemic attack / mini-stroke not exclusionary if symptoms lasted <1 week)
  • History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior to age 5 alongside a fever.
  • History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient ischemic attack not exclusionary)
  • Head injury that resulted in loss of consciousness lasting >30 minutes, cognitive issues lasting >18 months, and/or brain abnormalities visible in CT or MRI scan
  • Uncontrolled high blood pressure or diabetes
  • Heart attack within the last year

Treatment and study plan

Low-intensity focused ultrasound pulsation (LIFUP)

Device

Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)

Other names: transcranial focused ultrasound, tFUS, LIFUP, low intensity focused ultrasound

Primary outcomes

  1. Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal throughout Brain

    Time frame: 40 minutes

    Perfusion ASL fMRI data will be collected before and after sonication. Analyses will assess the statistical relationship between ASL signal throughout the brain pre and post sonication.

  2. Changes in BOLD-related functional connectivity from baseline in fMRI brain scan to 40 minutes.

    Time frame: 40 minutes

    Primary outcomes for proof of mechanism that may be depicted in the fMRI scans may include changes in BOLD-related functional connectivity increases within the DMN including regions functionally connected to the target.

    BOLD data will be collected before, during, and following LIFUP sonication. Analyses will assess any changes in BOLD signal in the brain following sonication.

Secondary outcomes

  1. Change in Brief Visual Memory Test Scores

    Time frame: 48 hours

    Potential LIFUP-related changes in memory will be assessed via neuropsychological assessments including the Brief Visual Memory Tests (BVMT). Scores range from 0 to 12 and reflect recent, long-term learning, with higher scores indicating better learning.

  2. Change in Verbal Learning Test Scores

    Time frame: 48 hours

    Potential LIFUP-related changes in memory will be assessed via the Rey Auditory Verbal Learning Test (RAVLT) neuropsychological assessment. The RAVLT involves providing participants with 15 unrelated words and asking them to recall the word list. There are 5 trials designed to determine short-term memory and then a 20 minute delay to assess long-term memory. The total words correct in both the short- and long-term trials are used as outcome measures.

  3. Post-hoc biomarker analysis of APOE-4 status as a predictor of tFUS efficacy

    Time frame: Baseline (pre-LIFUP)

    Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.

  4. Post-hoc biomarker analysis of plasma AB42/40 ratio as a predictor of tFUS efficacy

    Time frame: Baseline (pre-LIFUP)

    Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.

    An Aβ42/40 ratio <0.160 suggests a higher-than-normal risk of having of AD and is warranted to support a diagnosis of AD (West et al 2021).

  5. Post-hoc biomarker analysis of plasma ptau as a predictor of tFUS efficacy

    Time frame: Baseline (pre-LIFUP)

    Biomarker post hoc analysis will determine the degree to which blood based biomarkers predict the level of effectiveness of tFUS. Samples are collected before LIFUP is administered.

Study contacts

Contact information is provided by the study sponsor or research team.

Natalie Rotstein

CONTACT

[email protected]

‭(310) 794-0077‬

Sabrina Halavi

CONTACT

[email protected]

‭(310) 794-0077‬

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI

Acronym: LIFUP-MCIAD

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jun 14, 2022
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.